Now showing items 1-3 of 3

  • HBeAg-positive hepatitis delta: Virological patterns and clinical long-term outcome 

    Heidrich, B.; C. Serrano, B.; Idilman, R.; Kabaçam, G.; Bremer, B.; Raupach, R.; Önder, F. O.; Deterding, K.; Zacher, B. J.; Taranta, A.; Bozkaya, H.; Zachou, K.; Tillmann, H. L.; Bozdayi, A. M.; Manns, M. P.; Yurdaydin, C.; Wedemeyer, H. (2012)
    Background and Aims: The presence of the hepatitis B virus (HBV)-eAg in patients with hepatitis B is associated with higher HBV replication and with an increased risk to develop liver-related clinical endpoints defined as ...
  • Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta 

    Heidrich, B.; Yurdaydin, C.; Kabaçam, G.; Ratsch, B. A.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Tabak, F.; Yalcin, K.; Gürel, S.; Zeuzem, S.; Cornberg, M.; Bock, C. T.; Manns, M. P.; Wedemeyer, H. (2014)
    Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. ...
  • Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta 

    Kabaçam, G.; Wedemeyer, H.; Savaş, B.; Keskin, O.; Dalekos, G.; Tabak, F.; Idilman, R.; Erhardt, A.; Yalçin, K.; Bozdayi, M. A.; Bozkaya, H.; Manns, M.; Dienes, H.; Yurdaydin, C.; Berg, T.; Böcher, W.; Bohle, H.; Buggisch, P.; Cornberg, M.; Ers̈oz, G.; Feyerabend, S.; Hinrichsen, H.; Manok, M.; Häussinger, D.; Herzog, W.; Hofmann, W. P.; Plein, K.; Hardt, H.; Porst, H.; Mederacke, I.; Rigopoulou, E. I.; Sentürk, H.; Wagner, E. K. V. (2014)
    Background & Aims: Immunohistochemical assessment of liver tissue in chronic delta hepatitis (CDH) is underinvestigated. Aim of the study was (i) to assess variables associated with hepatitis D antigen (HDAg), hepatitis B ...